Cudetaxestat, a differentiated phase 2-ready investigational treatment for idiopathic pulmonary fibrosis
B. Elmankabadi (South San Francisco, United States), P. Ibrahim (South San Francisco, United States), C. Wong (South San Francisco, United States), R. Rajagopalan (South San Francisco, United States), X. Xu (South San Francisco, United States), W. Yu (South San Francisco, United States)
Source: International Congress 2022 – Interstitial lung diseases diagnosis in the COVID-19 era: new tools for new challenges
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Elmankabadi (South San Francisco, United States), P. Ibrahim (South San Francisco, United States), C. Wong (South San Francisco, United States), R. Rajagopalan (South San Francisco, United States), X. Xu (South San Francisco, United States), W. Yu (South San Francisco, United States). Cudetaxestat, a differentiated phase 2-ready investigational treatment for idiopathic pulmonary fibrosis. 459
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|